Test medications stop the process in mice
A natural chemical substance the eye calls for backup when it's lacking oxygen is responsible for the blinding blood vessel growth that plagues patients with diabetic retinopathy, report researchers at Johns Hopkins and CIBA Vision Corp., a Novartis Ltd. Pharmaceutical Co.
The work verifies earlier studies suggesting the substance, called vascular endothelial cell growth factor (VEGF), is a key culprit in abnormal blood vessel growth. In studies of laboratory mice, the team has identified medications that block the actions of the substance, completely stopping the abnormal vessels from growing.
Results are reported in the February issue of the American Journal of Pathology.
VEGF is released by the retina (light-sensitive tissue in back of the eye) when normal retinal blood vessels are damaged by disease, causing an oxygen deficiency. VEGF turns on its receptor, a switch that ignites a chain reaction culminating in new blood vessel growth. However, these backup blood vessels are faulty; they leak, bleed and encourage scar tissue that detaches the retina, resulting in severe loss of vision. Such growth is the hallmark of diabetic retinopathy, the leading cause of blindness in young people in developed countries.
Several factors in addition to VEGF have been thought to contribute to abnormal blood vessel growth, so finding that blocking the receptor for VEGF is enough "is a pleasant surprise that bodes well for drug treatment of the process," says Peter A. Campochiaro, M.D., senior author of the study and a professor of ophthalmology and neuroscience at Hopkins.
"Despite evidence that multiple substances are involved in the creation of abnormal blood vessels in the retina, we now know that stopping one of them, VEGF, is enough to completely block the process," he says. "By designing drugs that specifically block VEGF receptors, it should be possible to stop
Contact: Karen Infeld
Johns Hopkins Medical Institutions